Jenny Harry
Follow
Get notifications in MyBN when activity occurs.
Jenny Harry
Non-Executive Director / Genetic Signatures
Dr Jenny Harry has over 20 years of experience in executive management of companies in the biotechnology and biopharmaceutical sectors.
As chief executive and managing director of Tyrian Diagnostics, she transformed the company from an R&D business to a diagnostics company and oversaw development of the company's first products through to commercialisation and revenue generation.
Dr Harry also has expertise in creating effective organisation structures, building high performing teams, strategic planning, and negotiating with multi-national corporations on the development and commercialisation of products.
She received a PhD in Developmental Biology from Macquarie University, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors.
As chief executive and managing director of Tyrian Diagnostics, she transformed the company from an R&D business to a diagnostics company and oversaw development of the company's first products through to commercialisation and revenue generation.
Dr Harry also has expertise in creating effective organisation structures, building high performing teams, strategic planning, and negotiating with multi-national corporations on the development and commercialisation of products.
She received a PhD in Developmental Biology from Macquarie University, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors.
Lists and Charts
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 655th | Neuren Pharmaceuticals | 15% | 40% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Neuren Pharmaceuticals | $234.4m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| NEW ROLE: Non-Executive Director, Genetic Signatures | 08 Oct 2024 |
| NEW ROLE: Non-Executive Director, Aeris Environmental | 16 Jan 2023 |
| NEW ROLE: Non-Executive Director, Neuren Pharmaceuticals | 03 Nov 2020 |
